Skip to main content

First Zantac Bellwether Trial Slated On Feb 13, 2023

First Zantac Bellwether Trial Slated On Feb 13, 2023

First Zantac Bellwether Trial Slated On Feb 13, 2023

Introduction

A pretrial order to establish the first Zantac trial has been issued by a Californian State Court Judge who is overseeing the Ranitidine Products Cases JCCP NO. 5150.

The judge has confirmed the first four Zantac bellwether trials, with the first taking place on February 13, 2023, in Oakland.

The lawsuits allege that drug makers Boehringer Ingelheim, Sanofi, Pfizer, and GlaxoSmithKline (GSK) failed to warn about the link between Zantac and cancer. Thousands of claimants have welcomed the news.

As per the pretrial order from the judge, a Sargon hearing will take place on January 25, 2023, where the legal teams of both sides will present their expert witnesses. The court will consider the expert opinions and decide if both sides have used valid methodologies in their scientific opinions. If the judge approves the methodologies, then the Zantac cases in the JCCP can proceed to trial and experts would be allowed to present evidence and testimony which would determine if Zantac causes cancer.

The first bellwether trial will begin on February 13, 2023, if plaintiffs’ experts pass muster in SargonGenerally, the likelihood of the cases will end in settlement agreements if the plaintiffs win a jury verdict.

The second bellwether trial is scheduled on May 1, 2023, followed by a third trial scheduled on August 7, 2023. Bellwether trials will continue until the court appoints a mediator to negotiate resolutions or unless a global settlement has been reached.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

Purdue, Sacklers Agree to New $7.4B Opioid Settlement

Categories: Opioids

All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

This deal addresses allegations that the company’s aggressive and…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!